TALNIFLUMATE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C21H13F3N2O4
Molecular Weight	414.3341
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC(F)(F)C1=CC(NC2=C(C=CC=N2)C(=O)OC3OC(=O)C4=C3C=CC=C4)=CC=C1

InChI

InChIKey=ANMLJLFWUCQGKZ-UHFFFAOYSA-N

InChI=1S/C21H13F3N2O4/c22-21(23,24)12-5-3-6-13(11-12)26-17-16(9-4-10-25-17)19(28)30-20-15-8-2-1-7-14(15)18(27)29-20/h1-11,20H,(H,25,26)

HIDE SMILES / InChI

Molecular Formula	C21H13F3N2O4
Molecular Weight	414.3341
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.jocpr.com/articles/cluster-and-multilinear-regression-analyses-guided-identification-of-molecular-descriptors-that-account-for-cyclooxygena.pdf
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB09295 | https://www.drugs.com/international/talniflumate.html | https://www.ncbi.nlm.nih.gov/pubmed/15202731 | https://www.ncbi.nlm.nih.gov/pubmed/27879193 | https://www.ncbi.nlm.nih.gov/pubmed/14606981

Talniflumate, a prodrug of niflumic acid, is a potent analgesic and anti-inflammatory drug that has been used for the treatment of rheumatoid diseases. Talniflumate was synthesized by the esterification of a carboxyl group of niflumic acid with the phthalidyl moiety, and it exerts activity in the body through conversion to niflumic acid. Talniflumate has been studied as a mucoregulator for the treatment of cystic fibrosis, chronic obstructive pulmonary disease, and asthma. However, development of these indications appears to have been discontinued. Talniflumate has been approved and marketed for almost 20 years in Argentina and selected other countries (excluding the United States, Europe, and Japan).

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Calcium-activated chloride channel 1 Target ID: CHEMBL2364708 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17604505	Inhibitor 8297
Cyclooxygenase 89 Target ID: CHEMBL2094253 Sources: http://www.jocpr.com/articles/cluster-and-multilinear-regression-analyses-guided-identification-of-molecular-descriptors-that-account-for-cyclooxygena.pdf	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Rheumatoid arthritis 316 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14606981/	Primary	Approved 8429	Huluma Approved Use Unknown
Osteoarthritis 157 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14606981/	Primary	Approved 8429	Huluma Approved Use Unknown
Cystic fibrosis 120 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17604505	Primary	Phase II 1132	Huluma Approved Use Unknown

PubMed

Title	Date	PubMed
Talniflumate (Genaera).	2004 May	15202731

Patents

Sample Use Guides

In Vivo Use Guide

370mg, 3 times a day

Route of Administration: Oral

In Vitro Use Guide

Human pancreatic cancer cell line (MIA PaCa and BxPC-3) were used for activity evaluation. Cells were were incubated with different concentrations of Talniflumate (50, 100, 150 and 200 mkM), gefitinib and the combination of talniflumate and gefitinib for 24h. Cell viability was determined using the MTT method.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:19:30 GMT 2023` Edited by `admin` on `Fri Dec 15 16:19:30 GMT 2023`
Record UNII	JFK78S0U9S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TALNIFLUMATE

Official Name

English

Talniflumate [WHO-DD]

Common Name

English

BA 7602-06

Code

English

BA-7602-06

Code

English

TALNIFLUMATE [MART.]

Common Name

English

SOMALGEN

Brand Name

English

TALNIFLUMATE [USAN]

Common Name

English

talniflumate [INN]

Common Name

English

TALNIFLUMATE [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C257